Skip to main content
. 2017 Jul 8;8(40):67990–68000. doi: 10.18632/oncotarget.19092

Figure 3. Roniciclib accumulates cells in G2/M phase and inhibits mitotic progression.

Figure 3

(A) Cell cycle analysis was performed to evaluate the DNA content using flow cytometry in 8505C, 8305C and KAT18 cells treated with placebo or roniciclib (25 nM) for 24 h. (B) Quantification analyses revealed that roniciclib (25 nM) significantly arrested cells in G2/M phase at 24 h in all three ATC cell lines. (C) The percentage of ATC cells in mitosis was assessed after treatment with placebo or roniciclib (25 nM) for 24 h. Cells were stained with DAPI and chromosome characteristics were evaluated using immunofluorescence confocal microscopy. Mitotic index was assessed with a minimum of 276 cells counted from at least ten different fields for each condition. Roniciclib significantly decreased the proportion of cells in mitosis in 8305C cell line. (D) The distribution of cells in mitosis was evaluated by counting a minimum of 28 mitotic cells by confocal microscopy for each condition in 8505C and KAT18 cell lines. Statistical analyses revealed roniciclib (25 nM for 24 h) significantly accumulated 8505C cells in metaphase and KAT18 cells in prophase.